Albendazole
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ALBENZA | — | 1996-06-11 | fda.gov ↗ |
Trials 73 · started per year
Also used as a comparator or background therapy in 59 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02845713 Comparator | Apr → Jun 2016 | filariasis | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07258173 Comparator | May → Sep 2026 expected | trichuriasis | Jennifer Keiser | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07045493 Comparator | Jul 2025 → Mar 2026 overdue | intestinal helminthiasis | International Centre for Diarrhoeal Disease Research, Bangladesh | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT04713787 Comparator | Sep 2024 → Jan 2026 overdue | trichuriasis | Asociacion Benefica Prisma | Recruiting | No outcome recorded |
| Phase 2 | NCT03435718 Comparator | Jul 2024 → Jul 2026 overdue | trichuriasis | Oxfendazole Development Group | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06184399 Background | Jun → Aug 2024 | ascariasis, hookworm infectious disease, trichuriasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 2 | NCT06070116 Comparator | Apr 2024 → Sep 2026 expected | ocular onchocerciasis | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05538767 Comparator | Sep 2022 → Apr 2023 | hookworm infectious disease | Jennifer Keiser | Completed | No outcome recorded |
| Phase 2 | NCT04188301 Comparator | Dec 2019 → Mar 2022 | onchocerciasis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT02636803 Comparator | Nov 2019 → Aug 2020 | helminthiasis | Johns Hopkins Bloomberg School of Public Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT03172975 Background | Mar 2018 → Dec 2024 | hookworm infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT07182305 Comparator | May 2017 → Apr 2021 | alveolar echinococcosis | Ministry of Health, Kyrgyzstan | Completed | No outcome recorded |
| Phase 2 | NCT00511004 Comparator | Jul 2007 → Feb 2014 | filariasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT06565507 Comparator | Dec 2026 → Mar 2030 expected | cysticercosis | Universidad Peruana Cayetano Heredia | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05124691 Comparator | Jan 2022 → Mar 2023 | intestinal helminthiasis | Barcelona Institute for Global Health | Terminated | No outcome recorded |
| Phase 2/3 | NCT03527732 Comparator | Sep 2018 → May 2020 | trichuriasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 2/3 | NCT02509481 Background | Jun → Nov 2015 | filariasis, malaria | Colorado State University | Completed | No outcome recorded |
| Phase 2/3 | NCT02725255 Comparator | May → Nov 2015 | anemia, dermatophytosis of scalp or beard, helminthiasis | Kenya Medical Research Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00441285 Comparator | Jan 2010 → Dec 2012 | cysticercosis, epilepsy | Universidad Peruana Cayetano Heredia | Completed | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT07661316 Comparator | Nov 2026 → Feb 2027 expected | ascariasis, hookworm infectious disease, strongyloidiasis, trichuriasis | Mundo Sano Foundation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07159373 Background | Mar 2026 → Jun 2027 expected | filariasis, scabies, strongyloidiasis | Medicines Development for Global Health | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06037876 Comparator | Oct → Nov 2023 | trichuriasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 3 | NCT04966702 Comparator | Mar 2022 → Apr 2024 | malaria | Barcelona Institute for Global Health | Completed | No outcome recorded |
| Phase 3 | NCT04311671 Background | May 2021 → Sep 2024 | onchocerciasis | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 3 | NCT04410406 Comparator | Aug 2020 → Oct 2024 | filariasis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03676140 Background | Oct → Dec 2018 | filariasis, scabies, strongyloidiasis, trachoma +1 | Lihir Medical Centre | Completed | No outcome recorded |
| Phase 3 | NCT03474276 Comparator | Jan → Dec 2018 | protein-energy malnutrition | Institut Pasteur | Completed | No outcome recorded |
| Phase 3 | NCT02947581 Comparator | Nov 2016 → Aug 2020 | cysticercosis | Universidad Peruana Cayetano Heredia | Terminated | No outcome recorded |
| Phase 3 | NCT02243644 Comparator | Mar 2014 → Oct 2015 | cysticercosis | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01722539 Background | Nov 2012 → Nov 2013 | — | University of Antwerp | Completed | No outcome recorded |
| Phase 3 | NCT00755560 Comparator | Sep 2008 → Jul 2015 | toxocariasis | Hospital de Niños R. Gutierrez de Buenos Aires | Unknown | No outcome recorded |
| Phase 3 | NCT00765024 Comparator | Jul 2008 → Apr 2010 | strongyloidiasis | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT00290823 Background | Apr 2006 → Mar 2011 | cysticercosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00283699 Comparator | Feb 2001 → Feb 2005 | cysticercosis | Columbia University | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT06631612 Background | Jan 2024 → Jan 2025 overdue | iron deficiency anemia | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04391998 Comparator | May 2020 → Aug 2021 | anemia | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT02597556 Comparator | Feb → May 2016 | diarrheal disease, intestinal helminthiasis | Oxford University Clinical Research Unit, Vietnam | Withdrawn | No outcome recorded |
| Phase 4 | NCT02641210 Background | Jan → Jun 2015 | chronic periodontitis | Federal University of Maranhao | Completed | No outcome recorded |
| Phase 4 | NCT01192802 Comparator | Aug 2010 → Jul 2012 | helminthiasis, intestinal disorder | Albert Schweitzer Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00659997 Comparator | Jun → Sep 2006 | ascariasis, trichuriasis | Natural History Museum, United Kingdom | Completed | No outcome recorded |
| Phase not applicable19 trials | ||||||
| — | NCT07707817 Background | Jul 2026 → Jul 2027 expected | intestinal helminthiasis, onchocerciasis, schistosomiasis | Uwemedimo Friday Ekpo | Recruiting | No outcome recorded |
| — | NCT06265870 Comparator | May 2024 → Dec 2025 overdue | eosinophil disorder | Prince of Songkla University | Recruiting | No outcome recorded |
| — | NCT06483880 Comparator | Feb 2024 → Jun 2025 | cystic echinococcosis | Ain Shams University | Unknown | No outcome recorded |
| — | NCT05949190 Background | Aug 2023 → Oct 2026 expected | postpartum depression | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| — | NCT05914363 Background | Apr 2023 → Aug 2024 | ascariasis, diarrheal disease, hookworm infectious disease, trichuriasis +1 | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| — | NCT05323396 Comparator | May 2022 → Aug 2023 | coinfection | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT03702530 Background | Dec 2018 → Sep 2019 | necatoriasis | Leiden University Medical Center | Completed | No outcome recorded |
| — | NCT03177993 Background | Jul → Nov 2017 | Nematoda infectious disease, filariasis, impetigo, scabies | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT03079388 Background | Feb 2017 → Sep 2019 | nutritional disorder, pregnancy disorder | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT02812615 Background | Jul 2016 → Jun 2022 | infectious disease, protein-energy malnutrition | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
| — | NCT02899936 Comparator | Jul 2016 → Apr 2017 | filariasis | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT02420574 Comparator | Feb → Apr 2014 | helminthiasis | University Ghent | Completed | No outcome recorded |
| — | NCT00857116 Comparator | Mar 2009 → Jun 2013 | tuberculosis | Linkoeping University | Completed | No outcome recorded |
| — | NCT00817713 Comparator | Jan 2009 → Sep 2010 | HIV infectious disease, helminthiasis | Swiss Tropical & Public Health Institute | Terminated | No outcome recorded |
| — | NCT01213576 Comparator | Jan 2009 → Feb 2012 | filariasis | London School of Hygiene and Tropical Medicine | Terminated | No outcome recorded |
| — | NCT01050452 Comparator | Oct 2007 → Aug 2009 | parasitic infectious disease | DBL -Institute for Health Research and Development | Completed | No outcome recorded |
| — | NCT01050374 Comparator | Oct 2007 → Oct 2008 | parasitic infectious disease | DBL -Institute for Health Research and Development | Completed | No outcome recorded |
| — | NCT01050517 Comparator | Oct → Dec 2007 | parasitic infectious disease | DBL -Institute for Health Research and Development | Completed | No outcome recorded |
| — | NCT00207753 Background | Feb → Mar 2005 | ascariasis, hookworm infectious disease, lice infestation, strongyloidiasis +1 | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 136 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALBENDAZOLE | “The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine),...” NCT06182176 ↗132“Participants were randomly assigned to one of three treatment arms. On the first and third days, all participants got albendazole 400 mg, and on the second day, albendazole...” PMID 38563751 ↗ Apr 2024 “World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected...” NCT06037876 ↗ “Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic...” NCT03598842 ↗ “evaluating the urine and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites across a variety of food/fast conditions, age, gender and body weight.” NCT04041427 ↗ “Albendazole single 400mg dose will be given for infection with Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus, Trichuris trichiura.” NCT05323396 ↗ “Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA).” NCT03177993 ↗ “receive emodepside, at a single oral dose of 5, 10, 15, 20, 25, or 30 mg; albendazole, at a single oral dose of 400 mg; or placebo” PMID 37195942 ↗ May 2023 “fixed dose combination (FDC) of albendazole (ALB) and ivermectin (IVM) as a single dose to treat Soil-Transmitted Helminths (STH)” NCT06282315 ↗ “all individuals over 1 year receive albendazole and those infected with tungiasis receive benzyl benzoate.” PMID 40480665 ↗ Jun 2025 “Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole” NCT02366884 ↗ “Because of the corticosteroid treatment, albendazole 400 mg OD will be given to participants for 3 days.” NCT04738812 ↗ “Treatment drugs: Albendazole (Zentel) tablets 200mg, Glaxo Wellcome Production France manufacturer .” NCT05208333 ↗ “Ivermectin (IVM) and albendazole (ALB) are administered in areas where onchocerciasis is co-endemic;” NCT02899936 ↗ “a single oral dose of ivermectin 150 μg/kg plus albendazole 400 mg (IA)” PMID 37205721 ↗ May 2023 “Albendazole treatment, 400 mg x 2/d (or mebendazole if adverse effects)” NCT02876146 ↗ “DEC 300 mg + Albendazole 400 mg co-administration” NCT02005653 ↗ “Ivermectim (IVM) plus Albendazole (ALB)” NCT02078024 ↗ “albendazole” NCT05914363 ↗ |
| Known as | 5-(prophylthio)-2-benzimidazole carbamate | “Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug.” NCT04713787 ↗ |
| Known as | ABZ | “Purpose: To assess the efficacy of three proposed anthelminthic combination regimens for the treatment of strongyloidiasis using real-time polymerase chain reaction (real-time...” PMID 41364144 ↗ Dec 20252“evaluating the urine and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites across a variety of food/fast conditions, age, gender and body weight.” NCT04041427 ↗ “Albendazole (ABZ) 400 mg” NCT04410406 ↗ |
| Known as | ALB | “This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB...” NCT01050452 ↗8“BACKGROUND: Albendazole (ALB) is administered annually to millions of children through global deworming programs targeting soil-transmitted helminths (STHs: Ascaris...” PMID 34665810 ↗ Oct 2021 “Both groups will be treated with a single oral administration of Diethylcarbamazine (DEC) 6 mg/kg + Albendazole (ALB) 400 mg + Ivermectin (IVR) 200 µg/kg (IDA).” NCT02845713 ↗ “fixed dose combination (FDC) of albendazole (ALB) and ivermectin (IVM) as a single dose to treat Soil-Transmitted Helminths (STH)” NCT06282315 ↗ “Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)” NCT06070116 ↗ “Ivermectin (IVM) and albendazole (ALB) are administered in areas where onchocerciasis is co-endemic;” NCT02899936 ↗ “FDC of Ivermectin (IVM) and ALB either at single or 3- day regimens” NCT05124691 ↗ “single dose albendazole (ALB) in school age children” NCT01327469 ↗ “Ivermectim (IVM) plus Albendazole (ALB)” NCT02078024 ↗ |
| Known as | Albendazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1483 ↗ |
| Known as | Albendazolum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1483 ↗ |
| Known as | Albenza | ChEMBL registry synonym — accepted as the source's own label CHEMBL1483 ↗ |
| Known as | Andazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1483 ↗ |
| Known as | BENDEX | “albendazole, 400 mg, single oral dose, (BENDEX)” NCT02420574 ↗ |
| Known as | Eskazole | ChEMBL registry synonym — accepted as the source's own label CHEMBL1483 ↗ |
| Known as | NSC-220008 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1483 ↗ |
| Known as | OVIS | “albendazole, 400 mg, single-oral dose, (OVIS)” NCT02420574 ↗ |
| Known as | SK&F 62979 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1483 ↗ |
| Known as | Valbazen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1483 ↗ |
| Known as | Zentel | “400 mg of albendazole (Zentel” NCT00396500 ↗ |
| Action | Inhibit | “Albendazole is thought to inhibit cytoplasmic microtubules in the worm's intestinal tract leading to decreased glucose uptake and depletion of glycogen stores in the worm.” NCT00507221 ↗ |
| Modality | Small molecule | “Albendazole is a benzimidazole carbamate derivative with activity against most nematodes and some other worms.” NCT00507221 ↗ |
| Route | Oral | “Albendazole and dexamethasone or placebo only is administered orally once daily on days 5-15.” NCT00004403 ↗ |